Adjunct therapies

Module 2: Different adjunct therapies

Please log in to access the chapters in this module.
CME Credits: 0.5
Module duration: 0.5 hours
Launch date: Summer 2019 (version 1)
Updated: Spring 2023 (version 2)
Expiry date: March 2027
Audience: Diabetes and Metabolism Specialists (Advanced)

Intensive insulin therapy is the mainstay of treatment of people with type 1 diabetes, but there are several issues with the way we administer insulin at the moment. Indeed, exogenous insulin is accompanied with weight gain, it is accompanied with risk of hypoglycaemia and, in particular, also with a risk of high variability of the glycaemic profile. So we are looking for many years already, for novel therapies to be added to insulin therapy in people with type 1 diabetes, the so-called adjunct therapies. We have been looking at therapies that have been used in people with type 2 diabetes, for instance metformin. But also for other therapies, like pramlintide. Let's discuss these adjunct therapies.

This module takes an in-depth look at clinical trials that have investigated the use of adjunct therapies to treat type 1 diabetes, including pramlintide, metformin, liraglutide and SGLT-2 inhibitors.

Petrie JR, Chaturvedi N, Ford I, Brouwers MCJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM, REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug; 5(8): 597–609. Published online 2017 Jun 11. doi: 10.1016/S2213-8587(17)30194-8.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641446/

Learning Outcomes

By the end of this module, you will be able to:

✓ Interpret the existing trial evidence related to the use of adjunct therapies in type 1 diabetes

✓ Explain the potential benefits and drawbacks of using adjunct therapies in the treatment of type 1 diabetes

✓ Develop treatment plans for people with type 1 diabetes based on current clinical trial evidence


This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.


Contributors

Professor
Chantal Mathieu
Author
Professor
Thomas Danne
Expert Reviewer
Dr
Muhammad Fahad Arshad
Assessment Setter
Dr
Meera Ladwa
Assessment Setter